News & Analysis as of

Amgen Federal Rules of Civil Procedure

Goodwin

Special Master Appointed to Decide Requests to Seal and Redact in Genentech v. Amgen BPCIA Litigations

Goodwin on

On March 30, in the Genentech v. Amgen trastuzumab and bevacizumab biosimilar patent litigations, Delaware District Judge Connolly ordered the appointment of a special master to handle the parties’ requests to seal various...more

Goodwin

Biologic and Biosimilar Litigation Updates

Goodwin on

In an update on the Amgen v. Coherus appeal regarding Coherus’s biosimilar application for pegfilgrastim, Amgen filed its opening brief on August 20. Amgen’s statement of the issues are...more

Foley & Lardner LLP

Federal Circuit Provides More Guidance On Biosimilar Patent Litigation

Foley & Lardner LLP on

In Amgen Inc. v. Hospira, Inc., the Federal Circuit held that Amgen could not obtain discovery related to activities that might infringe a patent that it had not asserted in its biosimilar patent litigation against Hospira....more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide